175 related articles for article (PubMed ID: 36499626)
21. The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration.
Ghasabi M; Majidi J; Mansoori B; Mohammadi A; Shomali N; Shirafkan N; Baghbani E; Kazemi T; Baradaran B
J Cell Physiol; 2019 Dec; 234(12):22581-22592. PubMed ID: 31111481
[TBL] [Abstract][Full Text] [Related]
22. miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases.
Liu J; Zhang X; Huang Y; Zhang Q; Zhou J; Zhang X; Wang X
Oncol Lett; 2019 Feb; 17(2):1453-1460. PubMed ID: 30675199
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
[TBL] [Abstract][Full Text] [Related]
24. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
Qin X; Sun L; Wang J
Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
[TBL] [Abstract][Full Text] [Related]
25. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy.
Yu JL; Gao X
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1688-1696. PubMed ID: 32141535
[TBL] [Abstract][Full Text] [Related]
27. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
28. NF-κB p65 promotes ovarian cancer cell proliferation and migration via regulating mortalin.
Li S; Lv M; Qiu S; Meng J; Liu W; Zuo J; Yang L
J Cell Mol Med; 2019 Jun; 23(6):4338-4348. PubMed ID: 30983127
[TBL] [Abstract][Full Text] [Related]
29. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
30. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.
Kazmierczak D; Jopek K; Sterzynska K; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008952
[TBL] [Abstract][Full Text] [Related]
31. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
Liu Y; Niu Z; Lin X; Tian Y
Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
[TBL] [Abstract][Full Text] [Related]
32. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
33. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
Rao YM; Shi HR; Ji M; Chen CH
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
[TBL] [Abstract][Full Text] [Related]
35. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
36. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
Guo P; Xiong X; Zhang S; Peng D
Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells.
Zhou Y; Chen Q; Qin R; Zhang K; Li H
Tumour Biol; 2014 Dec; 35(12):12369-78. PubMed ID: 25179844
[TBL] [Abstract][Full Text] [Related]
39. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
40. Oleuropein reduces cisplatin resistance in ovarian cancer by targeting apoptotic pathway regulators.
Hashemi Sheikhshabani S; Amini-Farsani Z; Rahmati S; Jazaeri A; Mohammadi-Samani M; Asgharzade S
Life Sci; 2021 Aug; 278():119525. PubMed ID: 33894272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
